NMRA approves Russia’s ‘Sputnik V’ vaccine | Daily News

NMRA approves Russia’s ‘Sputnik V’ vaccine

Uses same technology as AstraZeneca jab:
Offers 92% protection against COVID:
COVAX Vaccines too here on Sunday:

The National Medicines Regulatory Authority (NMRA) of Sri Lanka has approved the use of the Russian ‘Sputnik V’ COVID-19 vaccine.

Acting Health Minister and Pharmaceuticals Supply and Production State Minister Prof. Channa Jayasumana told the media that the Expert Committee of the NMRA had approved the vaccine for Emergency Use in Sri Lanka.

Sputnik V is a COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology of Russia and was registered on August 11 last year by the Russian Health Ministry. It was the first vaccine to be registered anywhere in the world for clinical (non-trial) use. Sputnik V is an adenovirus viral vector vaccine, the same technology used by AstraZeneca, the other vaccine approved for use in Sri Lanka.

It uses a cold-type virus, engineered to be harmless, as a carrier to deliver a small fragment of the coronavirus to the body. Safely exposing the body to part of the virus’s genetic code in this way allows it to recognise the threat and learn to fight it off, without risking becoming ill.

The NMRA granted their consent for the Emergency Use of the Oxford-AstraZeneca vaccine in the third week of January this year.

Accordingly, Sri Lankan health authorities are already administering the Oxford-AstraZeneca “Covishield” vaccine manufactured by the Serum Institute in India (SII), the world’s biggest vaccine manufacturer.

The country received 500,000 doses of the vaccine as a donation from India under its “Vaccine Maitri” programme on January 28. More than 550,000 persons around the country have already received the vaccine.